Baldur Sveinbjornsosn
Chief Scientific Officer Lytix Biopharma AS
Seminars
Wednesday 2nd December 2026
Insights Exchange – What Biological Features Are Still Missing From Today’s Tumour Models?
5:00 pm
- Which aspects of the tumour microenvironment remain most difficult to capture?
- How can advanced models be made more scalable and reproducible?
- What innovations will have the biggest impact on model relevance over the next five years?
- Audience Q&As
Wednesday 2nd December 2026
Evidence – Understanding Which Models Best Predict Systemic Responses to Intratumoral Immunotherapies
3:40 pm
- Exploring the limitations of traditional tumour models when evaluating immunemediated mechanisms of action
- Assessing how models can capture tumour antigen release, immune priming, and responses beyond the treated tumour site
- Applying translational learnings from intratumoral immunotherapy development to improve combination strategies and clinical translation
